



B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter J. Houzego, Peter N. Morgan, Peter H. Hirst, Duncan J. Westland and
Ian R. Wilding

Serial No.: Divisional of 09/742,936

Art Unit: Not Yet Assigned

Filed: June 27, 2003

Examiner: Not Yet Assigned

For:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449 and a copy of the document cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

Publications


ERIKSEN, et al., "Equipment and methodology for relating gastrointestinal absorption to site of drug release," *J. Pharm. Sci.* 49: 151-156 (1960).

U.S.S.N.: Divisional of 09/742,936
Filed: June 27, 2003
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.


Respectfully submitted,

A handwritten signature in black ink, appearing to be 'P. Pabst', written over a horizontal line.

Patrea L. Pabst
Reg. No. 31,284

Dated: July 16, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number

Divisional of 09/742,936

Filing Date

June 27, 2003

First Named Inventor

Peter J. Houzago

Group Art Unit

Examiner Name

Attorney Docket Number

PHAG 100 DIV

Sheet

1

of

1

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ERIKSEN, et al., "Equipment and methodology for relating gastrointestinal absorption to site of drug release," <i>J. Pharm. Sci.</i> 49: 151-156 (1960).	

Examiner's Signature		Date Considered	
-------------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

